BiotechTube

chlorambucil, tablets + ofatumumab (GSK1841157) infusion

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Leukaemia, Lymphocytic, Chronic

Conditions

Leukaemia, Lymphocytic, Chronic

Trial Timeline

Dec 22, 2008 → May 17, 2018

NCT ID
NCT00748189

About chlorambucil, tablets + ofatumumab (GSK1841157) infusion

chlorambucil, tablets + ofatumumab (GSK1841157) infusion is a phase 3 stage product being developed by Novartis for Leukaemia, Lymphocytic, Chronic. The current trial status is terminated. This product is registered under clinical trial identifier NCT00748189. Target conditions include Leukaemia, Lymphocytic, Chronic.

What happened to similar drugs?

2 of 7 similar drugs in Leukaemia, Lymphocytic, Chronic were approved

Approved (2) Terminated (2) Active (3)
✅AcalabrutinibAstraZenecaApproved
🔄Ofatumumab + Physicians' ChoiceNovartisPhase 3
🔄OFC Infusion + FC infusionNovartisPhase 3
❌NilotinibNovartisPhase 3
❌OfatumumabNovartisPhase 3
🔄Gemtuzumab ozogamicin + Liposomal daunorubicin + Mitoxantrone + Fludarabine + Cytarabine + Busulfan + CyclophosphamidePfizerPhase 3
✅OfatumumabGenmabApproved

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00748189Phase 3Terminated

Competing Products

20 competing products in Leukaemia, Lymphocytic, Chronic

See all competitors
ProductCompanyStageHype Score
AZD3632 + PosaconazoleAstraZenecaPhase 1/2
39
AZD1152 + C14 AZD1152AstraZenecaPhase 1
29
AcalabrutinibAstraZenecaApproved
50
AZD2811 + Azacitidine + VenetoclaxAstraZenecaPhase 1
21
Administration of AZD6738AstraZenecaPhase 1
29
AZD1152AstraZenecaPhase 1
29
AZD0486 + Prednisone (or equivalent) + Rituximab + Cyclophosphamide + Vincristine + Doxorubicin + AcalabrutinibAstraZenecaPhase 1/2
39
AZD2171AstraZenecaPhase 1
29
Nilotinib, Pegylated interferon alpha-2b, ImatinibMerckPhase 2
35
Ofatumumab + Physicians' ChoiceNovartisPhase 3
40
OFC Infusion + FC infusionNovartisPhase 3
40
NilotinibNovartisPhase 3
32
OfatumumabNovartisPhase 3
32
Daunorubicin + Cytarabine + Eltrombopag + PlaceboNovartisPhase 2
35
BlinatumomabAmgenPhase 1
29
Idelalisib + RituximabGilead SciencesPre-clinical
26
humanised monoclonal antibody, veltuzumab + humanised monoclonal antibody epratuzumab + humanised monoclonal antibodies veltuzumab and epratuzumabGilead SciencesPhase 1/2
28
BosulifPfizerPhase 2
31
Bosutinib + Imatinib + Nilotinib + Dasatinib + PonatinibPfizerPre-clinical
26
Gemtuzumab ozogamicin + Liposomal daunorubicin + Mitoxantrone + Fludarabine + Cytarabine + Busulfan + CyclophosphamidePfizerPhase 3
47